Advertisement
Research Article| Volume 20, ISSUE 5, P467-478, May 1985

Vitamin B6, magnesium, and combined B6-Mg: Therapeutic effects in childhood autism

DOI:https://doi.org/10.1016/0006-3223(85)90019-8
Vitamin B6, magnesium, and combined B6-Mg: Therapeutic effects in childhood autism
Previous ArticleIrreversible starvation
Next ArticleHypercalcemia in the etiology of puerperal psychosis
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      This article reports the behavioral, biochemical, and electrophysiological effects of four therapeutic crossed-sequential double-blind trials with 60 autistic children: Trial A— vitamin B6 plus magnesium/magnesium; Trial B—vitamin B6 plus magnesium; Trial C— magnesium; and Trial D—vitamin B6. Therapeutic effects were controlled using behavior rating scales, urinary excretion of homovanillic acid (HVA), and evoked potential (EP) recordings. The behavioral improvement observed with the combination vitamin B6-magnesium was associated with significant modifications of both biochemical and electrophysiological parameters: the urinary HVA excretion decreased, and EP amplitude and morphology seemed to be normalized. These changes were not observed when either vitamin B6 or magnesium was administered alone.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Agren H.
        • Osterberg B.
        • Niklasson F.
        • Franzen O.
        Depression and somatosensory evoked potentials: I. Correlations between SEP and monoamine and purine metabolites in CSF.
        Biol Psychiatry. 1983; 18: 635-649
        • Alexander P.E.
        • Van Kammen D.P.
        • Bunney W.E.
        Serum calcium and magnesium levels in schizophrenia. II. Possible relationship to extrapyramidal symptoms.
        Arch Gen Psychiatry. 1979; 36: 1372-1377
        • APA (American Psychiatric Association)
        3rd ed. Diagnostic and Statistical Manual of Mental Disorders. APA, Washington, DC1980 (DSM-III)
        • Barbeau A.
        • Rojo-Ortega J.M.
        • Brecht H.M.
        • Ganten D.
        • Minnich J.
        • Boucher R.
        • Genest J.
        Déficience en magnésium et dopamine cérébrale.
        in: Durlach J. First International Symposium on Magnesium Deficit in Human Pathology. II. Vol des Communications et Discussions. SGEMV, Vittel1973: 149-159
        • Barthélémy C.
        • Garreau B.
        • Leddet I.
        • Ernouf D.
        • Muh J.P.
        • Lelord G.
        Behavioral and biological effects of oral magnesium, vitamin B6 and combined magnesium-vitamin B6 administration in autistic children.
        Magnesium Bull. 1981; 2: 150-153
        • Bhagavan H.N.
        • Coleman M.
        • Coursin D.B.
        The effect of pyridoxine hydrochloride on blood serotonin and pyridoxal phosphate contents in hyperactive children.
        Pediatrics. 1975; 55: 437
        • Brooks S.C.
        • D'Angelo L.
        • Chalmeta A.
        • Ahern G.
        • Judson J.H.
        An unusual schizophrenic illness responsive to pyridoxine HC1 (B6) subsequent to phenothiazine and butyrophenone toxicities.
        Biol Psychiatry. 1983; 18: 1321-1328
        • Callaway E.
        Response of infantile autism to large doses of B6.
        Psychopharmacol Bull. 1977; 13: 57-58
        • Cohen D.J.
        Biogenic amines in autistic and atypical children. Cerebrospinal fluid measures of homovanillic acid and 5 hydroxyindoleacetic acid.
        Arch Gen Psychiatry. 1974; 31: 845-853
        • Cohen D.J.
        • Young T.G.
        Neurochemistry and child psychiatry.
        J Child Psychiatry. 1977; 16 (NY): 353-411
        • Coleman M.
        • Landgrebe M.A.
        • Landgrebe A.R.
        Celiac autism: Calcium studies and their relationship to celiac disease in autistic patients.
        in: Coleman M. The Austistic Syndromes. North Holland, Amsterdam1976: 197-205
        • Coleman M.
        • Greenberg A.
        • Bhagavan H.
        • Steinberg G.
        • Tippett J.
        • Coursin D.
        The role of whole blood serotonin levels in monitoring vitamin B6 and drug therapy in hyperactive children.
        Monogr Neural Sci. 1976; 3: 133-136
        • Coleman M.
        • Steinberg C.
        • Tippett J.
        • Bhagavan H.N.
        • Coursin D.B.
        • Gross M.
        • Lewis C.
        • Deveau L.
        A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: A double-blind crossover comparison with methylphenidate.
        Biol Psychiatry. 1979; 14: 741-751
        • Durlach J.
        Neurological manifestations of magnesium imbalance.
        in: Handbook of Clinical Neurology. vol. 28. North Holland, Amsterdam1976: 545-579
        • Durlach J.
        Aspects cliniques du déficit magnésique chronique.
        Vie Med. 1977; 6: 146-180
        • Ebadi M.
        • Costa E.
        Role of Vitamin B6 in Neurobiology.
        Raven, New York1972
        • Elchisak M.A.
        • Polinsky R.J.
        • Ebert M.M.
        • Powers K.J.
        • Kopin I.J.
        Contribution of plasma homovanillic acid (HVA) to urine and cerebrospinal fluid HVA in the monkey and its pharmacokinetic disposition.
        Life Sci. 1978; 23: 2339-2348
        • Garreau B.
        • Barthélémy C.
        • Domenech J.
        • Sauvage D.
        • Muh J.P.
        • Callaway E.
        • Lelord G.
        Troubles du métabolisme de la dopamine chez des enfants ayant un comportement autistique: Résultats des examens cliniques et des dosages urinaires de l'acide homovanilique (AHV).
        Acta Psychiatr Belg. 1980; 80: 240-265
        • Garreau B.
        • Barthélémy C.
        • Jouve J.
        • Bruneau N.
        • Muh J.P.
        • Lelord G.
        Urinary levels of homovanillic acid (HVA) in children with autistic behavior.
        Am J Child Psychiatry. 1984; (in press)
        • Gillberg C.
        • Svennerholm L.
        • Hamilton-Hellberg C.
        Childhood psychosis and monoamine metabolites on spinal fluid.
        J Austism Dev Dis. 1983; 13: 383-396
        • Heinrich P.
        Mg dependent ATPase in membranes of 5HT storage organelles.
        Biochem Biophys Res Commun. 1972; 46: 1769-1775
        • Jackson M.J.
        • Garrod P.J.
        Plasma zinc, copper and amino acid levels in the blood of autistic children.
        J Austism Child Schizophr. 1978; 8: 203-208
        • Kopin I.
        Measuring turnover of neurotransmitters in human brain.
        in: Lipton M.A. Damasio A. Killan K.G. Psychopharmacology: A Generation of Progress. Raven, New York1978
        • Korf J.
        • Ottema S.
        • Van Derveen J.
        Fluorimetric determination of homovanillic acid in biological material after isolation on Sephadex G10.
        Anal Biochem. 1971; 40: 187-191
        • Lelord G.
        • Callaway E.
        • Muh J.P.
        • Sauvage D.
        • Arlot J.C.
        L'acide homovanilique urinaire et ses modifications par ingestion de vitamine B6: Exploration fonctionnelle dans l'autisme de l'enfant?.
        Rev Neurol. 1978; 124: 797-801
        • Lelord G.
        • Muh J.P.
        • Barthélémy C.
        • Martineau J.
        • Garreau B.
        Effects of pyridoxine and magnesium on autistic symptoms. Initial observations.
        J Autism Dev Dis. 1981; 11: 219-230
        • Lelord G.
        • Callaway E.
        • Muh J.P.
        Clinical and biological effects of high doses of vitamin B6 and magnesium on autistic children.
        Acta Vitaminol Enzymol. 1982; 4: 27-44
        • Mahanand D.
        • Wypych M.K.
        • Calcagno P.L.
        Serum zinc and copper levels in autistic patients and matched controls.
        in: Coleman M. The Autistic Syndromes. North Holland, Amsterdam1976: 73-76
        • Martineau J.
        • Laffont F.
        • Bruneau N.
        • Roux S.
        • Lelord G.
        Event-related potentials evoked by sensory stimulation in normal, mentally retarded and autistic children.
        Electroenceph Clin Neurophysiol. 1980; 48: 140-153
        • Martineau J.
        • Garreau B.
        • Barthélémy C.
        • Callaway E.
        • Lelord G.
        Effects of vitamin B6 on averaged evoked potentials in infantile autism.
        Biol Psychiatry. 1981; 16: 627-641
        • Martineau J.
        • Garreau B.
        • Barthélémy C.
        • Lelord G.
        Comparative effects of oral B6 Mg and Mg administration on evoked potentials conditioning in autistic children.
        in: Rothenberger A. Event-related Potentials in Children. Elsevier Biomedical, New York1982: 411-416
        • Novick B.
        • Vaughan H.G.
        • Kurtzberg D.
        • Simon R.
        An electrophysiologic indication of auditory processing defects in autism.
        Psychiat Res. 1980; 3: 107-115
        • Ornitz E.M.
        • Ritvo E.R.
        • Panman L.E.
        • Lee Y.H.
        • Carr E.M.
        • Walker R.D.
        The auditory evoked response in normal and autistic children during sleep.
        Electroenceph Clin Neurophysiol. 1968; 25: 221-230
        • Pausescu E.
        • Lugojan R.
        • Pausescu M.
        Cerebral catecholamines and serotonine metabolism in post-hypothermic brain oedema.
        Brain. 1970; 93: 31-36
        • Pfeiffer C.C.
        • Bacchi D.
        Copper, zinc, manganese, niacin and pyridoxine in the schizophrenias.
        J Appl Nutr. 1975; 27: 9-39
        • Pfeiffer C.C.
        • Braverman E.R.
        Zinc, the brain and behavior.
        Biol Psychiatry. 1982; 17: 513-532
        • Pfeiffer C.C.
        • Iliev V.
        • Goldstein L.
        • Jenney E.H.
        Serum polyamine levels in schizophrenia and other objective criteria of clinical status.
        in: Sankar Siva Schizophrenia: Current Contents and Research. PJD Publications, Hicksville, NY1969: 557-563
        • Pfeiffer C.C.
        • Iliev U.
        A study of zinc deficiency and copper excess in the schizophrenias.
        Int Rev Neurobiol Suppl. 1972; : 142-165
        • Redmond D.E.
        • Borge G.F.
        • Buchsbaum M.
        • Maas J.W.
        Evoked potentials studies of brain catecholamine alteration in monkeys.
        J Psychiatr Res. 1975; 12: 97-116
        • Rimland B.
        An orthomolecular study of psychotic children.
        Orthomolec Psychiatry. 1974; 3: 371-377
        • Rimland B.
        • Callaway E.
        • Dreyfus P.
        The effects of high doses of vitamin B6 on autistic children: A double blind cross over study.
        Am J Psychiatry. 1978; 135: 472-475
        • Saladino C.F.
        • Siva Sankar D.V.
        Studies of erythrocyte magnesium and potassium levels in childhood schizophrenia and growth.
        Behav Neuropsychiatry. 1968; 1: 24-28
        • Saletu B.
        • Saletu M.
        • Simeon J.
        • Masara J.
        Fluphenazine treatment in the psychotic child: Clinical evoked potentials correlations.
        Comp Psychiatry. 1975; 16: 265-278
        • Schafer E.W.
        • MacKean C.M.
        Evidence that monoamines influence human evoked potentials.
        Brain Res. 1975; 99: 49-58
        • Small J.
        • Demyer M.
        • Kendall J.
        Experience with response averaging in autistic children.
        Electroenceph Clin Neurophysiol. 1969; 26: 112-113
        • Swann A.C.
        • Mass J.M.
        • Hattox S.E.
        • Landis H.
        Catecholamine metabolites in human plasma as indices of brain functions: Effects of debrisoquin.
        Life Sci. 1980; 25: 1857-1862
        • Von Knorring L.
        • Monakhov K.
        • Perris C.
        Augmenting-reducing: An adaptive switch mechanism to cope with incoming signals in healthy subjects and psychiatric patients.
        Neuropsychobiology. 1978; 4: 150-179
        • Wadman S.K.
        • Ketting D.
        • Voute P.A.
        Gas chromatographic determination of urinary vanilglycol acid, vanilglycol, vanilacetic acid and vanilactic acid. Chemical parameters for the diagnosis of neurogenous tumours and the evaluation of their treatment.
        Clin Chim Acta. 1976; 72: 49-68

      Article info

      Publication history

      Received in revised form: November 26, 1984
      Received: July 10, 1984

      Footnotes

      ☆Supported by CNRS (ERA No. 697) “Biology and Neuropsychiatry,” INSERM, ATP 78–97.

      Identification

      DOI: https://doi.org/10.1016/0006-3223(85)90019-8

      Copyright

      © 1985 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX